UnknownNot Applicable

Hydrodissection of the Hepatoduodenal Ligament

France13 participantsStarted 2022-07-20

Plain-language summary

Percutaneous treatment of liver lesions adjacent to the duodenum exposes the duodenum to the risk of thermal injury, limiting removal and oncologic outcome. In this study the investigators investigate the feasibility of hepato duodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Major subject (≥18 years of age) * Subject who underwent percutaneous ablation of primary or secondary liver lesions at HUS that required per-procedure hepatoduodenal ligament hydrodissection in the interventional imaging department of the New Civil Hospital from January 2019 to July 2022. * Subject who has not expressed opposition to the reuse of their data for the purpose of this research. Exclusion Criteria: \- Opposition to the reuse of his/her data for the purpose of scientific research.

What they're measuring

Retrospective description of the hepatoduodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum

Timeframe: Files analysed retrospectively from January 01, 2019 to July 31, 2022 will be examined

Trial details

NCT IDNCT06190821

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-02

Contact for this trial

Julien GARNON, MD

33 3.69.55.03.04 julien.garnon@chru-strasbourg.fr

View on ClinicalTrials.gov More Hepatic Lesions trials